clinicaltrialsarena3h
Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints
Kashiv Biosciences has reported that a trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary ...
clinicaltrialsarena21h
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
clinicaltrialsarena21h
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...
clinicaltrialsarena21h
Allakos cuts 75% of workforce after chronic hives trial failure
A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.
clinicaltrialsarena5h
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial
Degrees Pharmaceuticals has received approval from the IRB for a Phase II trial of Arakoda (tafenoquine) for treating chronic babesiosis.
clinicaltrialsarena1d
Akero’s cirrhosis treatment shows promise in Phase IIb study
Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...